Jumping on the gravy train

Clarus Venturesand Aisling Capitaljumped on an opportunity to return money to investors through potential royalties for cancer compound ibrutinib, but the firms don't plan to make a habit of investing in royalty streams.

The firms paid just under $97 million last week to acquire a 20% stake of Royalty Pharma's royalty stream for the Bruton's tyrosine kinase (Btk) inhibitor...